Skip to content
‹ Back to IndustriesSciences

Pfizer and Chinese Biotech Company Team Up

NetVation DL Medicine (DL Medicine), a biopharmaceutical company based in China, has scored a two-year collaboration deal with Pfizer, one of the largest companies in the industry. Together, these companies will conduct research into innovative treatments for patients around the world. Furthermore, the deal allows Pfizer to take a financial stake in the Chinese company….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · ·
Share
Pfizer and Chinese Biotech Company Team Up

Key takeaways

01

NetVation DL Medicine (DL Medicine), a biopharmaceutical company based in China, has scored a two-year collaboration deal with Pfizer, one of the largest companies in the industry.

02

Together, these companies will conduct research into innovative treatments for patients around the world.

03

Furthermore, the deal allows Pfizer to take a financial stake in the Chinese company….

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

NetVation DL Medicine (DL Medicine), a biopharmaceutical company based in China, has scored a two-year collaboration deal with Pfizer, one of the largest companies in the industry. Together, these companies will conduct research into innovative treatments for patients around the world. Furthermore, the deal allows Pfizer to take a financial stake in the Chinese company.

What Will the Companies Research?

Even before this deal with Pfizer, DL Medicine partnered with HitGen to access the company’s DNA-encoded library. The latest partnership will allow all companies involved to leverage this database to discover new interventions for a variety of illnesses.

“We are delighted to announce this collaboration with Pfizer, and we look forward to working together to potentially discover new chemical entities for the treatment of diseases that negatively impact the health of patients worldwide,” said Dr. Wei Chen, the CEO of DL Medicine. As the former leader of drug discovery at HitGen, Chen is intimately familiar with the DNA-encoded library and the program’s potential.

As is the nature of these deals, the exact cures and treatments this partnership may produce is a mystery. However, DL Medicine has made breakthroughs in metabolic, inflammatory, and cancer-related diseases in the past. It’s likely that we’ll continue to see innovation in those areas.

Why Pfizer Invested

As part of this agreement, Pfizer made a serious financial investment in the smaller company, DL Medicine. Yuan-Hua Ding, the Executive Director of External Science and Innovation at Pfizer, believes this research will help the global business heal more patients than ever before.

“New target ideas and novel chemical matter are critical to our success in bringing new therapies to patients around the world,” he said. “This collaboration represents our worldwide commitment to partnering with companies that are doing innovative scientific work to help enhance our portfolio across multiple disease areas.”

Why China?

It’s probably no accident that Pfizer chose a China-based company as its partner in this endeavor. Not only is DL Medicine uniquely qualified to take on this project, but the company is also situated in a booming research and development market. Over the past 20 years, China has become a global leader in scientific discovery. In fact, the country has soared past both the United States and the European Union in this area regarding money spent and outcomes.

The newfound partnership between DL Medicine and Pfizer may bring about some critical medical advancements. Learn more about DL Medicine and Pfizer to follow this significant deal.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Lab Thread's MCP server lets scientists ask their own AI assistant about lab records

Lab Thread's MCP server lets scientists ask their own AI assistant about lab records

Lab Thread has launched a Model Context Protocol server that lets scientists query their lab records from ChatGPT, Claude or other AI assistants. The server runs inside Lab Thread's cloud with audit logs aligned to 21 CFR Part 11, so the audit trail stays with the record system. The company also opened a Boston office.

  • 01For a regulated lab, the useful question about any AI connector is where the audit log lives. Lab Thread keeps it inside its own tenant-isolated cloud and shares only the minimum context each authorized query needs.
  • 02Pinning an MCP server version doesn’t lock its transitive dependencies, so the code that runs can still change between builds. If Lab Thread’s MCP server is vendor-hosted in its secure cloud, the local install/package chain would be the vendor’s to manage rather than something each scientist launches on a laptop.
  • 03Before connecting an assistant, ask what the audit log records for each AI query: the user, the records touched and the context sent outside the platform.

Nov 20, 2026

Uncountable adds cleanroom monitoring aimed at linking results into QMS, CAPA and batch-traceability workflows

Uncountable adds cleanroom monitoring aimed at linking results into QMS, CAPA and batch-traceability workflows

Uncountable’s monitoring module maps sampling points and, per Cleanroom Technology, can tie results into CAPA and batch/training traceability when linked records are populated.

  • 01Proving a sample was taken is the easy part of an Annex 1 inspection; showing what the result means for the batch filled in that room depends on how monitoring records connect to CAPA, batch and training files.
  • 02Uncountable's module records whether a cleanroom was at rest or in operation for every sample, so results can be trended by room state, method and location instead of reviewed one excursion at a time.
  • 03Before buying any monitoring software, ask which linked records a site will actually populate, how the system behaves without connectivity, and how instrument telemetry gets in, since Uncountable does not ingest sensor data natively.

Nov 19, 2026

PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached

PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached

PharmaLogic is buying Lantheus' contract manufacturing unit and Springfield, New Jersey radiopharmaceutical plant, plus a long-term deal to make lutetium Lu 177 dotatate for Lantheus. Radioligand developers looking for capacity should ask how much of the plant's capacity is still open.

  • 01A long-term supply contract attached to a plant sale could help keep costly hot-cell capacity in use. According to Grand View Research, committed supply agreements are among the tools that help providers align capital spending with customer development milestones.
  • 02Radioligand developers evaluating PharmaLogic's Agilera unit should ask how much Springfield capacity the lutetium Lu 177 dotatate contract will take up and how much is left for new programs.
  • 03Two pending transactions shape what to watch next: regulatory review and closing conditions for the PharmaLogic purchase, and Curium’s August offer of upward of $8 billion for Lantheus, which is still closing.

Nov 18, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512